P1121 MATCHING-ADJUSTED INDIRECT COMPARISONS OF EPCORITAMAB VSMOSUNETUZUMAB OR ODRONEXTAMAB IN RELAPSED/REFRACTORYFOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES

Kim Linton, et al.

Research output: Contribution to journal › Meeting Abstract › peer-review

Filter

2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Linton, K. M., Vitolo, U., Jurczak, W., Lugtenburg, P. J., Gyan, E., Sureda, A., Christensen, J. H., Hess, B., Tilly, H., Cordoba, R., Lewis, D. J., Okada, C., Hutchings, M., Clausen, M. R., Sancho, J. M., Cochrane, T., Leppä, S., Chamuleau, M. E. D., Gernhardt, D. & Altıntaş, I. & 8 others, Liu, Y., Ahmadi, T., Dinh, M. H., Hoehn, D., Favaro, E., Elliott, B., Thieblemont, C. & Vose, J. M., Aug 2024, In: The Lancet Haematology. 11, 8, p. e593-e605
Research output: Contribution to journal › Article › peer-review

Research output